media – Page 29 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Maghreb Pharma Expo

Organiser: Easy Fairs Time：April 21, 2026 – April 23, 2026 address：Palais des expositions Pins Maritimes Alger 16000, Algiers, Algeria Exhibition hall：Safex Expo Center Product range: Medical Products Section: Medical diagnostic equipment and supplies, electronic medical equipment and instruments, rescue equipment, medical reagents and devices, etc. Hospital Supplies Section: Catheters, interventional materials, surgical hygiene products, disposable medical consumables, surgical instruments, medical clothing and bedding, emergency equipment, maternal and child care equipment, sterilization equipment, etc. Laboratory Equipment Section: Laboratory instruments and equipment, optical instruments and equipment, image analysis and processing systems, testing instruments and devices, laboratory renovation and upgrading technologies, consumables, and related software, etc. Pharmaceuticals Section: Various new and specialty drugs, traditional Chinese medicines, Western medicines, Chinese herbal health products, nutritional foods, etc.; traditional medicines, Chinese herbs, herbal remedies, etc. Pharmaceutical Equipment Section: Pharmaceutical production equipment and technologies, pharmaceutical packaging equipment, pharmaceutical packaging materials, pharmaceutical production, cleaning, and sterilization systems. ...
- Source: drugdu
- 105
- October 9, 2025
The application for marketing authorization of trivalent influenza virus split vaccine has been accepted

People’s Finance News reported on September 24 that Kangtai Biological(300601) announced on September 24 that the influenza vaccine developed by the companyThe application for marketing authorization of the viral split vaccine recently received an acceptance notice issued by the National Medical Products Administration. The influenza virus split vaccine 　　whose marketing authorization application was accepted this time is a trivalent influenza vaccine. Together with the quadrivalent influenza virus split vaccine that the company has applied for production registration, the quadrivalent influenza virus split vaccine (for people aged 6-35 months) that has been approved for clinical trials, the quadrivalent influenza virus split vaccine (MDCK cells) and the trivalent influenza virus split vaccine (MDCK cells), they constitute an influenza vaccine series covering all age groups. https://finance.eastmoney.com/a/202509243522587919.html
- Source: drugdu
- 88
- October 8, 2025
Walvax Biopharma’s vaccine receives Jordanian Drug Registration Certificate, marking a key step forward in its Middle East market expansion.

　　Shanghai Securities News China SecuritiesNet News (Reporter Sun Zhong) Walvax BioAn announcement on the 29th stated that the 13-valent pneumococcal polysaccharide conjugate vaccine produced by its subsidiary Yuxi Walvax recently received a “Drug Registration Certificate” issued by the Jordan Food and Drug Administration. 　　The Yuxi Walvax 13-valent pneumococcal polysaccharide conjugate vaccine is mainly suitable for vaccination of infants and children aged 6 weeks to 5 years (before the age of 6 years). It is used to prevent infectious diseases caused by the 13 serotypes of pneumococcus contained in this vaccine (type 1, type 3, type 4, type 5, type 6A, type 6B, type 7F, type 9V, type 14, type 18C, type 19A, type 19F and type 23F). The vaccine was approved for sale in China in 2020. 　　Currently, pneumococcal infection remains one of the leading causes of death in children under five worldwide. In Jordan, this infection also poses a ...
- Source: drugdu
- 103
- October 8, 2025
Zhifei Bio’s independent product, influenza virus split vaccine, has obtained a drug registration certificate

　　Zhifei BioinfluenzaThe vaccine matrix has added another blockbuster product. The company announced on the evening of September 29 that the influenza virus split vaccine (referred to as “trivalent influenza vaccine”; registration category: preventive biological product) recently developed by its wholly-owned subsidiary, Anhui Zhifei Longcom Biopharmaceutical Co., Ltd.) Obtain the “Drug Registration Certificate” issued by the State Food and Drug Administration. 　　Influenza is an acute respiratory infectious disease caused by the influenza virus that can cause widespread epidemics. It is highly contagious and can cause complications such as pneumonia, bronchitis, and myocarditis. It can aggravate underlying conditions in high-risk groups such as the elderly and the frail, increasing the disease burden and endangering human health. Flu vaccination is the most economical and effective measure to prevent influenza illness and influenza outbreaks. The trivalent influenza vaccine developed by Zhifei Longcoma is suitable for people aged three years and older to prevent infectious ...
- Source: drugdu
- 108
- October 8, 2025
【EXPERT Q&A】What are the key points and requirements for the product registration application materials of Class II active medical devices?

Drugdu.com expert’s response: I. Requirements for Completeness of Declaration Materials Basic Certification Documents Business License: Submit a copy of the enterprise’s valid business license (with expiration date). Personnel Qualifications: Provide identity certificates and educational/professional title certificates for the legal representative, enterprise负责人 (enterprise leader), and quality manager to verify enterprise and personnel qualifications. Contract Manufacturing: If outsourcing production, submit the contract manufacturer’s Medical Device Production License and the signed contract manufacturing agreement between both parties. Core Product Documents Medical Device Registration Application Form: Detailed description of product name, specifications, model, structure, intended use, production process, and quality control methods. Must be signed and stamped by the legal representative or responsible person. Product Instructions and Label Specimens: Include generic name, model, specifications, manufacturer information, product technical requirement number, production date, expiration date, performance, structure, intended use, contraindications, and precautions. Product Technical Requirements: Specify technical parameters, performance indicators, and testing methods in compliance with national/industry ...
- Source: drugdu
- 105
- October 8, 2025
Antihypertensive and lipid-lowering drugs show efficacy against steatotic liver disease

Metabolic dysfunction-associated steatotic liver disease is the most common liver disease in the world, affecting about one third of the adult population. This disorder is characterized by the accumulation of fat in liver cells, which has severe liver consequences and is also associated with a high mortality rate from cardiovascular disease. Now, a University of Barcelona study published in the journal Pharmacological Research shows that pemafibrate and telmisartan, two drugs already approved for other conditions, effectively reduce fat accumulation in laboratory animal models of metabolic liver disease. Furthermore, the study suggests that this combination of drugs may help to reduce both liver involvement and associated cardiovascular complications. These results open the door to the development of safer and more effective treatments for this disease, for which current therapeutic options are very limited. The study has been carried out by a team led by Marta Alegret, professor at the ...
- Source: drugdu
- 160
- October 7, 2025
Large-scale analysis offers insights into sporadic nature of chikungunya virus outbreaks

While the virus is common in tropical and subtropical regions, including Asia, Africa and South America, public health officials have been tracking reported infections in Europe and, in September, a confirmed case in Long Island, New York. Outbreaks of chikungunya have prompted the Centers for Disease Control to issue health notices to travelers bound for Bangladesh; Cuba; Guangdong Province, China; Kenya; Madagascar; Somalia; and Sri Lanka. In Guangdong Province, an”unprecedented”outbreak recently prompted government officials in China to mandate quarantines for anyone suspected of being infected by the virus, spraying individuals with mosquito repellent and spraying impacted buildings and other areas with insecticide. In a new study, published in Science Advances, researchers at the University of Notre Dame analyzed more than 80 outbreaks of chikungunya virus to improve prediction of future outbreaks and inform vaccine trial development. “Chikungunya outbreaks are unpredictable in both size and severity,”said Alex ...
- Source: drugdu
- 138
- October 7, 2025
The KOREA PHARM & BIO

Organiser: Korea Food and Drug Administration (KFDA), Korea Pharmaceutical Manufacturers Association (KPMA) Time：March 31, – April 3, 2026 address：217-60 KINTEX-ro, Ilsanseo-gu, Goyang-si, Gyeonggi-do, Republic of Korea (Daehwa-dong) Exhibition hall：KINTEX (Korea International Exhibition Center) Product range: Pharmaceuticals: Pharmaceutical raw materials, APIs (Active Pharmaceutical Ingredients), pharmaceutical fine chemicals, intermediates, pharmaceutical additives, drug formulations, natural extracts, biotechnology, pharmaceutical outsourcing and services, laboratory equipment, pharmaceutical manufacturing equipment, etc. Chemicals: Chemical raw materials, chemical equipment, instrumentation, automation control technology, heat exchangers, crystallization, gas absorption, drying, filtration, centrifugal separators, dust removal, chemical reactors, crushers, mixers, etc. Cosmetics: Cosmetic raw materials, cosmetic additives, functional materials, natural extracts, etc. About The KOREA PHARM & BIO ： The KOREA PHARM & BIO is one of the most influential pharmaceutical and biotechnology exhibitions in Korea and across Asia. It is jointly organized by the Korea Food and Drug Administration (KFDA), the Korea Pharmaceutical Manufacturers Association (KPMA), and Kyungyon Exhibition Co., ...
- Source: drugdu
- 132
- October 7, 2025
UK health agency urges people to get vaccinated against respiratory viruses before winter

The UK Health and Safety Agency (UKHSA) announced on the 26th that as winter approaches, influenzaThe number of cases of COVID-19, COVID-19 and respiratory syncytial virus (RSV) is on the rise, and the public is urged to make appointments for relevant vaccines as soon as possible. 　　The latest UK national influenza and COVID-19 surveillance report shows that related cases have been steadily increasing over the past few weeks. The COVID-19 positive rate has risen from 7.6% to 8.4% in one week, and the number of COVID-19 hospitalizations per 100,000 people has also increased from 2 to 2.73. UKHSA emphasizes that before the peak season of respiratory diseases arrives, people should receive timely medical treatment from the UK National Health Service.The free vaccinations are provided by the National Health Service (NHS). Pregnant women and millions of children are already eligible for the vaccine, and most eligible groups can make an appointment from October 1. This ...
- Source: https://finance.eastmoney.com/a/202509263525102518.html
- 141
- October 6, 2025
Beike Bio responded to the inquiry letter regarding its semi-annual report and detailed the reasons for the decline in herpes zoster vaccine sales.

Beike BioA response was made to the regulatory inquiry letter regarding information disclosure in the 2025 semi-annual report, mentioning the reasons for the decline in sales of shingles vaccine. 　　In the first half of 2025, the company’s operating income was 285 million yuan, a year-on-year decrease of 53.93%; the net profit was -73.5734 million yuan, turning from profit to loss year-on-year. The company disclosed that the decline in performance was mainly due to the decline in sales of shingles vaccine. 　　The announcement showed that during the reporting period, the company’s sales volume of shingles vaccine was -17,300 doses, with sales revenue of -65.2266 million yuan. 　　Beike Bio believes that factors such as product price structure, vaccination demand, low disease awareness, insufficient consumption willingness of the applicable group, and vaccine hesitation affect the product revenue. 　　The company stated in its response that during the reporting period, sales of herpes zoster vaccines decreased ...
- Source: https://finance.eastmoney.com/a/202509303526642756.html
- 144
- October 6, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.